Latest From BlueWillow Biologics
Suzhou-based immuno-oncology specialist CStone raised a $260m Series B round and Brii launched with $260m in Series A cash to develop drugs for the China market. Also, multiple start-ups launched recently with more than $50m in Series A rounds, including Ansun, Beam, Casma, Celsius and Neurana.
Big venture capital bets continue in biopharma, including Foresite's new $668m fund and Merck's $125m investment in Moderna, but small VC rounds could be making a comeback. In public company financings, Aslan and Evelo launched in the US, while Ascletis is testing Hong Kong’s IPO market.
The fourth quarter of 2013 offered a mixed bag for biotechnology licensing deals; there were fewer transactions, but with much higher upfront payments than in previous quarters, according to law firm Morrison & Foerster's BioMeter report.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Recent Financings of Start-Ups column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Pharmaceuticals, and Medical Devices sectors.
- Nanotechnology, Chips, etc.
- Topical Delivery
- Drug Delivery
- Therapeutic Areas
- Infectious & Viral Diseases
- Respiratory, Pulmonary
- NanoBio Corp.
- North America
- Parent & Subsidiaries
- BlueWillow Biologics
- Senior Management
David Peralta, CEO
Tarek Hamouda, MD, PhD, Sr. Dir., Clinical Research
- Contact Info
Phone: (734) 302-4000
2311 Green Rd.
Ann Arbor, MI 48105
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.